RxDoctor Payments Data

Pranahitha Reddy, MD

Psychiatry · Independence, MONPI 1215979281

Payments from drug & device makers

$1,228in general payments, 2019–2025

Across 33 payments — averaging $37.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$465
  • Otsuka America Pharmaceutical, Inc.$160
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$125
  • Alkermes, Inc.$103
  • Johnson & Johnson$100
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$74
  • plus $201 from 6 others

What the payments were for

  • Food & beverage$1,228100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,228 in reported general payments places this provider in the 70th percentile of 680 psychiatry providers in Missouri.

See all psychiatry providers in Missouri

Medicare billing

Part B allowed, 2024
$8,624
Medicare patients
32
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate24$88,943
VraylarCariprazine Hcl25$38,254
Abilify MaintenaAripiprazole11$31,897
AristadaAripiprazole Lauroxil13$31,130
Lurasidone Hcl48$10,873
Aripiprazole120$6,698
BelsomraSuvorexant12$5,533
Hydroxyzine Hcl125$2,589
Quetiapine Fumarate96$1,796
Fluphenazine Hcl14$1,624
Duloxetine Hcl58$1,555
Bupropion XlBupropion Hcl98$1,490
Buspirone Hcl92$1,458
Oxcarbazepine24$1,226
Trazodone Hcl187$1,156

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna$100$88,94324 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$160$31,89711 claims
Alkermes, Inc.Aristada$103$31,13013 claims
Teva Pharmaceuticals USA, Inc.Loxapine$11$9212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 680 psychiatry providers in Missouri.

Other psychiatry in Independence

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →